HNCIG-6/NRG HN002 RESULTS PUBLISHED IN JCO

January 28, 2021

This randomized phase II trial for good-risk HPV-associated OPSCC compared reduced-dose radiation (60 Gy) with or without concurrent weekly cisplatin. The RT-only arm was accelerated at 6 fractions per week. The accelerated reduced-dose radiation alone arm failed to meet statistical conditions for PFS acceptability, whereas the CRT arm did, justifying its advancement as a study arm of NRG-HN005. https://ascopubs.org/doi/full/10.1200/JCO.20.03128

Recent Posts

See All

ARTICLE ON THE FORMATION OF THE HNCIG PUBLISHED IN ORAL ONCOLOGY

July 10, 2017 An article describing the formation of the HNCIG as well as its objectives, structure, and activities was published in Oral...

HNCIG CONSENSUS GUIDELINES FOR POSTOPERATIVE RADIATION IN COMPLEX CUTANEOUS SQUAMOUS CELL CARCINOMA

HNCIG CONSENSUS GUIDELINES FOR POSTOPERATIVE RADIATION IN COMPLEX CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK July 15, 2020...

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY...

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY DURING THE COVID-19 PANDEMIC PUBLISHED IN RED...

HNCIG-6/NRG HN002 RESULTS PUBLISHED IN JCO

Recent Posts

Comentários